Cervical Cancer Growth Is Regulated by a c-ABL-PLK1 Signaling Axis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27899378.
- Also identified by DOI 10.1158/0008-5472.CAN-16-1378.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The nonreceptor tyrosine kinase c-ABL controls cell growth but its contributions in solid tumors are not fully understood. Here we report that the Polo-like kinase PLK1, an essential mitotic kinase regulator, is an important downstream effector of c-ABL in regulating the growth of cervical cancer. c-ABL interacted with and phosphorylated PLK1. Phosphorylation of PLK1 by c-ABL inhibited PLK1 ubiquitination and degradation and enhanced its activity, leading to cell-cycle progression and tumor growth. Both c-ABL and PLK1 were overexpressed in cervical carcinoma. Notably, PLK1 tyrosine phosphorylation correlated with patient survival in cervical cancer. In a murine xenograft model of human cervical cancer, combination treatment with c-ABL and PLK1 inhibitors yielded additive effects on tumor growth inhibition. Our findings highlight the c-ABL-PLK1 axis as a novel prognostic marker and treatment target for human cervical cancers. <i>Cancer Res; 77(5); 1142-54. ©2016 AACR</i>.
Medical subject headings
- Cell Cycle Proteins
- Protein Serine-Threonine Kinases
- Proto-Oncogene Proteins
- Proto-Oncogene Proteins c-abl
- Uterine Cervical Neoplasms